Are immunotherapies for Huntington’s disease a realistic option?
| Autor: | Hélèna L Denis, Francesca Cicchetti, Florian Lauruol |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
business.industry Genetic disorder Inflammation Disease Bioinformatics medicine.disease Pathophysiology Vaccination Clinical trial 03 medical and health sciences Cellular and Molecular Neuroscience Psychiatry and Mental health Huntington Disease 030104 developmental biology 0302 clinical medicine Immune system Huntington's disease medicine Humans Immunotherapy medicine.symptom business Molecular Biology 030217 neurology & neurosurgery |
| Zdroj: | Molecular Psychiatry. 24:364-377 |
| ISSN: | 1476-5578 1359-4184 |
| DOI: | 10.1038/s41380-018-0021-9 |
| Popis: | There is compelling evidence that the pathophysiology of many neurodegenerative diseases includes dysregulation of the immune system, with some elements that precede disease onset. However, if these alterations are prominent, why have clinical trials targeting this system failed to translate into long-lasting meaningful benefits for patients? This review focuses on Huntington's disease, a genetic disorder marked by notable cerebral and peripheral inflammation. We summarize ongoing and completed clinical trials that have involved pharmacological approaches to inhibit various components of the immune system and their pre-clinical correlates. We then discuss new putative treatment strategies using more targeted immunotherapies such as vaccination and intrabodies and how these may offer new hope in the treatment of Huntington's disease as well as other neurodegenerative diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink